Documents

A list of downloadable documents created during development.

Expected publication

Final appraisal determination

Appraisal consultation

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): final scope (post referral)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): final matrix (post referral)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): NICE response to scope and matrix (post referral)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): equality impact assessment (post referral)

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): draft scope for consultation (pre-referral) - January 2015

Melanoma (BRAF V600, advanced, unresectable, metastatic) - cobimetinib (with vemurafenib): provisional matrix (pre-referral) - January 2015